Overview Cancer pain pump


Patients report a reduction in pain scores after receiving targeted drug delivery.

What is targeted drug delivery?

Targeted drug delivery (TDD) provides effective pain relief by delivering medication directly to the fluid surrounding the spinal cord via a programmable pump.1-5

  • At 4 weeks, more patients receiving TDD  plus conventional medical management (CMM) reported a pain score less than 4 compared with those receiving CMM alone.1 On a 0-10 pain scale, below 4 marks the point at which patients can assume more normal role function.1
  • 85% of patients receiving TDD and CMM reported at least 20% reduction in pain score or fewer side effects; 58% reported at least 20% relief and fewer side effects.1
  • At 6 months, patients providing baseline and follow-up data reported significant improvements in pain and quality of life compared to baseline.3
  • At 4 weeks, 87.5% of patients were able to discontinue systemic opioids with TDD and 92% remained off systemic opioids at 8 weeks.4
  • The number of patients with severe pain (≥7) related to pancreatic cancer decreased from 89.2% before TDD to 4.5% after 1 week, 6.7% after 1 month, and 10.3% after 3 months of pump implant.5

Targeted drug delivery is an option for cancer pain management and is commonly known as a “pain pump.”

Bessie’s story

“I feel better than I have felt in years. It has given me a new lease on life.”

A system for cancer pain relief

Discover how the SynchroMed™ II pump and myPTM™ personal therapy manager deliver pain relief. 

Find out more

Full-body MRI scans

Medtronic SynchroMed II pump was designed to be safe under certain conditions for patients who may require an MRI scan.*

Learn about scans
Find a physician

Talk with a doctor and see if the Medtronic cancer pain pump is right for you.


MR yellow triangleUnder specific conditions. Talk to your doctor and refer to product labeling for full list of conditions.


Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040-4049.


Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357-366.


Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal drug delivery systems for cancer pain: An analysis of a prospective, multicenter product surveillance registry. Anesth Analg. 2020;130(2):289-297.


Brogan SE, Sindt JE, et al. Prospective association of serum opioid levels and clinical outcomes in patients with cancer pain treated with intrathecal opiod thearpy. Anesth Anal 2020;130:1035-44


Carvajal G, Dupoiron D, Seegers V, et al. Intrathecal drug delivery systems for refractory pancreatic cancer pain: Observational follow-up study over an 11-year period in a comprehensive cancer center. Anesth Analg. 2018;14:14.

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.